Core Viewpoint - The company emphasizes its commitment to investor returns through various methods, including cash dividends, investor relations management, information disclosure, and share buybacks, while focusing on enhancing operational efficiency and profitability through innovation and strategic investments [1] Group 1: Investor Returns - The company has implemented continuous dividends for six years since its listing, with a total dividend payout of 788 million yuan, and the dividend ratio for the 2024 fiscal year has been increased to 40.31% [1] - The actual controller's concerted actors have increased their holdings in the company three times, with a total investment of approximately 384 million yuan [1] - The company has launched three rounds of share buyback plans, with a cumulative buyback amount of about 249 million yuan as of December 31, 2025 [1] Group 2: Share Buyback and Cancellation - To fulfill commitments regarding the buyback plan and enhance investor returns, the company canceled 1,459,586 shares from its buyback on January 6, 2026 [1] Group 3: Business Strategy and Growth - The company focuses on enhancing value creation capabilities through technological innovation, scenario upgrades, and globalization to improve operational efficiency and profitability [1] - It aims to accelerate investment and acquisition processes to strengthen existing industries and expand business boundaries, thereby reshaping its industrial development pattern and enhancing core competitiveness and investment value [1]

证券日报网讯 1月9日，海尔生物在互动平台回答投资者提问时表示，近年来受到复杂多变的全球和行 业形势等因素影响，公司业绩有所波动。今年前三季度，公司展现出较强的发展韧性，业绩于第二季度 触底后，在第三季度实现反弹，新产业占公司主营业务收入的比重已提升至48%；海外市场表现尤其亮 眼，今年前三季度收入增幅达20%、占公司主营业务收入的比重为36%，而过去六年来公司海外业务复 合增长率为25%，海外市场竞争力为公司业绩持续复苏提供了重要支撑。此外，公司持续推进"AI+"与 四大产业的深度融合，为公司市场份额提升和用户价值创造提供重要支撑，数智自动化样本方案前三季 度实现了翻番增长。未来，公司将继续坚持技术创新、场景升级和全球化发展，并加强与投资者的交 流。 （文章来源：证券日报） ...

证券日报网讯 1月9日，海尔生物发布公告称，公司已完成注册资本工商变更登记手续，并取得了青岛 市行政审批服务局换发的《营业执照》。 （文章来源：证券日报） ...

Core Viewpoint - Haier Biomedical has outlined its four major industry layouts, focusing on providing comprehensive biological safety solutions and integrated management systems across various healthcare and research sectors [2] Group 1: Industry Layouts - The low-temperature storage industry targets biological objects such as samples, pharmaceuticals, vaccines, and blood, offering solutions that cover a temperature range from -196°C to 8°C [2] - The laboratory solutions industry serves users in research, pharmaceuticals, and testing, providing comprehensive solutions that include general instruments, analytical instruments, consumables, and software [2] - The blood technology industry focuses on whole blood and component blood collection and preparation, offering intelligent solutions for blood stations and plasma stations, including collection equipment, consumables, and pharmaceuticals [2] - The smart medication industry addresses the full-process automated management needs of hospital pharmacies, inpatient pharmacies, infusion centers, and fever clinics, providing solutions for drug "transfer-distribution-use" [2]

Core Viewpoint - The company emphasizes that technological self-reliance is driving the industry towards domestic production, which further expands its development space and enhances market competitiveness across its four major industries [1] Market Position and Performance - The company's market share in the low-temperature storage industry continues to increase, with a projected market share of over 50% in plasma collection solutions by mid-2025, based on public and third-party bidding data [1] - The company ranks among the top three in the automated medication market and continues to break through in the domestic market for scientific instruments, with its total organic carbon analyzers and UV spectrophotometers being the top two domestic brands [1] - The centrifuge series has entered the top ten in market share among industry brands, while the biological safety cabinet has risen to the number one position nationwide, and the cultivation series maintains the highest market share among domestic brands [1] International Market Presence - Preliminary market research indicates that the company's three major low-temperature product lines hold the leading market share in 25 overseas countries [1]

（文章来源：证券日报） 证券日报网讯 1月9日，海尔生物在互动平台回答投资者提问时表示，公司将持续提升价值创造能力， 不断强化信息披露工作，并通过各种方式增强与各类投资者的沟通，积极向资本市场传递公司价值。 ...

证券日报网讯1月9日，海尔生物在互动平台回答投资者提问时表示，公司以价值创造能力的提升为己 任，坚持技术创新、场景升级和全球化发展来提升上市公司经营效率和盈利能力，并基于"大市场、小 细分、多产品、多应用"的行业特点，加快投资并购进程补强现有产业、扩大业务边界，重塑自身产业 发展格局，不断增强公司的核心竞争力和投资价值。基于行业的常态化发展和公司核心竞争力的提升， 经初步测算，随着新建产能逐步释放和创新品类加速放量，利润端有望在2026年迎来拐点(上述内容依 据目前可获得的公开信息及管理层初步测算做出，不构成公司对任何投资者或第三方的业绩承诺、盈利 预测或前瞻性陈述，敬请投资者注意风险)。 ...

证券日报网讯1月9日，海尔生物在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东总 数为13105户。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2026-003 青岛海尔生物医疗股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 1 法定代表人：刘占杰 注册资本：316,492,922 元 成立日期：2005 年 10 月 28 日 住所：山东省青岛市高新区丰源路 280 号 经营范围：医疗器械的技术研发、生产、销售、售后服务及维修保养；制冷 设备、机电设备、冷库、液氮生物容器、太阳能制冷产品、实验室设备、消毒器 械、自动化仪器设备、电子产品、通讯产品、家用及商用电器、汽车电器的技术 开发、生产、销售和售后服务；冷藏服务；物联网技术开发、咨询服务、系统集 成；自动化管理系统、计算机集成系统的技术开发、销售和运维服务；软件技术 开发、销售、运维服务和技术咨询；计算机网络技术开发、技术咨询；第二类增 值电信业务；互联网信息服务；医疗器械互联网信息服务；化工产品（不含危险 化学品及一类易制毒化学品）、生物制品、仪器仪表、实验室耗材、家具、办公 自动化设备的销售；汽 ...

【#格力电器CMO炮轰创维抄袭##格力朱磊让创维下次别抄了#】格力电器CMO朱磊于微博发文炮轰创 维电器称，"抄得挺像的，下次别抄了。" 据朱磊发布配图内容，于创维空调官方视频号发布的一则创维空调海报设计页面，与格力推出的"真铜 实料 格力造"海报高度相似，明显涉嫌抄袭。 不过，目前该发布于创维空调视频号的海报已经删除。对于涉嫌抄袭一事，截至发稿创维方面暂无回 应。（新浪科技） ...